Home

Pfizer (PFE)

22.44
+0.00 (0.00%)
NYSE · Last Trade: Apr 16th, 9:30 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close22.44
Open-
Bid22.54
Ask22.58
Day's RangeN/A - N/A
52 Week Range20.92 - 31.54
Volume200,471
Market Cap125.81B
PE Ratio (TTM)15.91
EPS (TTM)1.4
Dividend & Yield1.680 (7.49%)
1 Month Average Volume67,801,840

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

Will Pfizer Approach Viking Therapeutics With A Buyout Proposatalkmarkets.com
Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill.
Via Talk Markets · April 15, 2025
Why Pfizer Stock Topped the Market on Tuesdayfool.com
Via The Motley Fool · April 15, 2025
Most active S&P500 stocks in Tuesday's sessionchartmill.com
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · April 15, 2025
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Studybenzinga.com
Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study.
Via Benzinga · April 15, 2025
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?fool.com
Via The Motley Fool · April 15, 2025
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullishstocktwits.com
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.
Via Stocktwits · April 15, 2025
Top Analyst Reports For Bank Of America, Chevron & Strykertalkmarkets.com
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation, Chevron Corporation, and Stryker Corporation, as well as two micro-cap stocks, Value Line, Inc. and Sypris Solutions, Inc.
Via Talk Markets · April 14, 2025
What's going on in today's session: S&P500 most active stockschartmill.com
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · April 14, 2025
This Strategy Always Outperforms In Bear Marketsbenzinga.com
Via Benzinga · April 14, 2025
Trump’s Trade Twist Sends Stocks Soaringtalkmarkets.com
Stocks are firmly higher Monday, as a surprise tariff exemption from President Donald Trump sparked a rally in the tech sector.
Via Talk Markets · April 14, 2025
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmovedstocktwits.com
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.
Via Stocktwits · April 14, 2025
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Todayfool.com
Pfizer bows, but is not entirely out of the GLP-1 race.
Via The Motley Fool · April 14, 2025
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?benzinga.com
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.
Via Benzinga · April 14, 2025
Meta’s Antitrust Trial Over Instagram, WhatsApp Acquisition To Begin Today: Chief Legal Officer Says FTC’s Case ‘Ignores Reality’stocktwits.com
The social media giant acquired Instagram in 2012 for $1 billion and WhatsApp in a highly competitive bid in 2014 for a whopping $19 billion, beating Google to the punch.
Via Stocktwits · April 14, 2025
Breaking New Study: mRNA Vaccines Trigger 620% Heart Risk Surge in Young Men
A groundbreaking study published in the International Journal of Cardiovascular Research & Innovation reveals alarming long-term heart risks linked to COVID-19 mRNA vaccines, challenging official narratives and raising urgent safety concerns. Contact: Lynne@imahealth.org
Via Newsworthy · April 14, 2025
Pfizer Discontinues Once-Daily Weight Loss Pill Over Liver Injury In One Patientbenzinga.com
Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.
Via Benzinga · April 14, 2025
Starbucks Updates Dress Code For Baristas To Offer Consistent Experiencestocktwits.com
Baristas must wear a solid black top and a denim bottom in any shade of khaki, blue, or black.
Via Stocktwits · April 14, 2025
Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shatteredstocktwits.com
The company plans to file a certification of dissolution with the Secretary of the State of Delaware in the third quarter of 2025, provided that stockholders authorize the decision at its annual meeting of stockholders on June 5.
Via Stocktwits · April 14, 2025
Pfizer Ends Development Of Weight Loss Pill Due To Potential Drug-Induced Liver Injury In A Patientstocktwits.com
According to Pfizer, the reported patient’s liver enzymes “recovered rapidly” after they stopped taking the company’s experimental weight loss pill.
Via Stocktwits · April 14, 2025
Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injuryinvestors.com
The company is continuing to test a daily pill that blocks GIPR.
Via Investor's Business Daily · April 14, 2025
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.
By Pfizer Inc. · Via Business Wire · April 14, 2025
SaveRxCanada.to Offers Affordable Access to Palbociclib (Ibrance) from India
April 14, 2025 -- Breast Cancer Patients Can Save Thousands Monthly with Trusted Generic "Palnat" at Just $4.38 Per Capsule
Via 24-7 Press Release · April 14, 2025
Benzinga Bulls And Bears: Apple, Nike, US Steel — And The Markets Ride Out Ongoing Volatilitybenzinga.com
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · April 12, 2025
1 Deeply Undervalued Stock to Buy in the Market Correctionfool.com
Via The Motley Fool · April 12, 2025
Which S&P500 stocks are the most active on Friday?chartmill.com
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Friday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · April 11, 2025